The Christie NHS Foundation Trust

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: -

Established: 2007-01-01

Employees: -

Market Cap: -

Website: http://www.christie.nhs.uk/

Clinical Trials

Serial Tumour Biopsies and Blood Biomarkers in Melanoma

Recruiting

Conditions: Melanoma

Interventions: Procedure: Surgery
Procedure: Venepuncture

First Posted Date: 2020-07-30

Last Posted Date: 2020-07-30

Lead Sponsor: The Christie NHS Foundation Trust

Target Recruit Count: 300

Registration Number: NCT04493723

Locations: 🇬🇧
The Christie, Manchester, United Kingdom

Remote Monitoring of Cancer Patients With Suspected Covid-19

Phase 1

Conditions: COVID
Oncology
Haematological Malignancy

Interventions: Device: Patient Status Engine

First Posted Date: 2020-05-21

Last Posted Date: 2021-02-11

Lead Sponsor: The Christie NHS Foundation Trust

Target Recruit Count: 30

Registration Number: NCT04397705

Locations: 🇬🇧
The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom

Developing Lung Cancer Screening in Hodgkin Lymphoma Survivors: a Qualitative Study

Completed

Conditions: Hodgkin Lymphoma

First Posted Date: 2020-05-20

Last Posted Date: 2020-09-03

Lead Sponsor: The Christie NHS Foundation Trust

Target Recruit Count: 30

Registration Number: NCT04396119

Locations: 🇬🇧
Christie NHS Foundation Trust, Manchester, United Kingdom

PDAC Peripheral and Portal Vein Sampling

Not Applicable

Completed

Conditions: Pancreatic Adenocarcinoma

Interventions: Diagnostic Test: Portal vein sampling

First Posted Date: 2020-02-28

Last Posted Date: 2023-08-30

Lead Sponsor: The Christie NHS Foundation Trust

Target Recruit Count: 26

Registration Number: NCT04289961

Locations: 🇬🇧
Manchester University NHS Foundation Trust, Manchester, United Kingdom
🇬🇧
The Christie NHS Foundation Trust, Manchester, United Kingdom

The CAPER Trial: A Phase Ib Clinical Trial of Cyclophosphamide And PEmbrolizumab in Metastatic Renal Cell Carcinoma

Phase 1

Conditions: Metastatic Renal Cell Carcinoma

Interventions: Drug: Cyclophosphamide 50mg
Drug: Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA]

First Posted Date: 2020-02-10

Last Posted Date: 2022-08-23

Lead Sponsor: The Christie NHS Foundation Trust

Target Recruit Count: 21

Registration Number: NCT04262427

Locations: 🇬🇧
Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
🇬🇧
Western General Hospital, NHS Lothian, Edinburgh, United Kingdom
🇬🇧
Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom

and more 1 locations

Remote Monitoring of Patients at Risk of Sepsis

Not Applicable

Conditions: Cancer
Sepsis
Neutropenia, Febrile

Interventions: Device: Lifetemp/Lifetouch sensors

First Posted Date: 2020-02-07

Last Posted Date: 2020-02-07

Lead Sponsor: The Christie NHS Foundation Trust

Target Recruit Count: 15

Registration Number: NCT04260230

Locations: 🇬🇧
The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom

A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer

Phase 2

Not yet recruiting

Conditions: Breast Cancer

Interventions: Drug: Avelumab
Drug: Lansoprazole
Drug: Aspirin

First Posted Date: 2019-12-05

Last Posted Date: 2023-05-17

Lead Sponsor: The Christie NHS Foundation Trust

Target Recruit Count: 42

Registration Number: NCT04188119

Patient Experience of Consent for Cancer Surgery in Light of Recent Changes to UK Law- a Questionnaire Study

Completed

Conditions: Patient Satisfaction

First Posted Date: 2019-07-18

Last Posted Date: 2019-07-18

Lead Sponsor: The Christie NHS Foundation Trust

Target Recruit Count: 39

Registration Number: NCT04024189

Locations: 🇬🇧
The Christie NHS Foundation Trust, Manchester, United Kingdom

The Goals of Care Initiative

Not Applicable

Terminated

Conditions: Decision-Making Oncology
Chemotherapy Effect

Interventions: Behavioral: Goals of Care Initiative

First Posted Date: 2019-07-16

Last Posted Date: 2021-06-21

Lead Sponsor: The Christie NHS Foundation Trust

Target Recruit Count: 220

Registration Number: NCT04020679

Locations: 🇬🇧
The Christie NHS Foundation Trust, Manchester, United Kingdom

Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma

Phase 2

Active, not recruiting

Conditions: Neuroendocrine Carcinoma
Oncology

Interventions: Drug: Liposomal Irinotecan
Drug: Docetaxel
Drug: Fluorouracil
Drug: Folinic Acid

First Posted Date: 2019-02-12

Last Posted Date: 2023-06-09

Lead Sponsor: The Christie NHS Foundation Trust

Target Recruit Count: 102

Registration Number: NCT03837977

Locations: 🇬🇧
The Beaston West of Scotland Cancer Center, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
🇬🇧
Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom
🇬🇧
The Christie NHS Foundation Trust, Manchester, United Kingdom

and more 1 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy